JPRN-UMIN000009702已完成2 期
Efficacy of Aprepitant for Hematology and Oncology. - Efficacy of Aprepitant for Hematology and Oncology.
Kyoto University Hospital,Department of Hematology and Oncology0 个研究点目标入组 30 人开始时间: 2013年1月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
Frequency of nausea and vomitting decreased with the addition of aprepitant.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. chemotherapy within 6 days before study day 1 or between days 1 to 6. 2.Antiemetic therapy prior to 48 hr of chemotherapy. 3.Corticosteroids therapy within 72 hr before study day 1 or duration of study 4.Radiation therapy to the abdomen or pelvis within 6 days before study day 1 or duration of study 5.known central nervous system malignancy 6.following drug therapy within 6 days before study day 1 - clarithromycin, ketoconazole, itraconazole - 7. following drug therapy within 4 weeks before study day 1 - barbiturate, rifampicin, phenytoin, carbamazepine - 8. pregnant, nursing or possibly pregnant women 9.Patients judged inappropriate for this study by physicians
研究者
相似试验
招募中
3 期
Clinical Trial Study of the Effect of Apripitant Drug on Nausea and Vomiting Due to Chemotherapy in Childrenausea and vomiting.Nausea and vomiting of childrenIRCT2017080520715N3Vice chancellor for research, Arak University of Medical Sciences60
已完成
不适用
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric PatientsNauseaVomitingNCT00956215University of Pennsylvania125
已完成
1 期
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerNausea and VomitingBreast CancerNCT00719173UNC Lineberger Comprehensive Cancer Center19
进行中（未招募）
4 期
The Effect of Aprepitant Reducing Postoperative Nausea and VomitingNausea and Vomiting, PostoperativeObesityNCT05772676Hospital General Tlahuac400
已完成
2 期
Efficacy of Aprepitant for Hematology and Oncology.Hematological cancerJPRN-UMIN000005705Kyoto University Hospital,Department of Hematology and Oncology52